Epigenetic aberrations and a CpG island methylator phenotype are associated with poor outcome in children with neuroblastoma (NB). Previously, we have shown that valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, exerts antitumor effects in an NB xenograft model. However, the underlying antitumor molecular mechanisms are largely unknown. In this study, we examined the role of HDAC in cell proliferation, cell cycle progression, gene expression patterns, and epigenome in NB. Cell proliferation, cell cycle progression, caspase activity, RNA and protein expression, quantitative methylation, and global DNA methylation were examined in NBL-W-N and LA1-55n NB cell lines. Our studies showed that inhibition of HDAC decreased NB proliferation, and induced caspase activity and G 1 growth arrest. Expression patterns of cancer-related genes were modulated by VPA. The expression of THBS1, CASP8, SPARC, CDKN1A, HIC1, CDKN1B, and HIN1 was upregulated, and that of MYCN and TIG1 was downregulated. HDAC inhibition decreased methylation levels of THBS1 and RASSF1A promoters.
Introduction
Neuroblastoma (NB) is the most common pediatric extracranial solid tumor and is characterized by its broad spectrum of clinical behavior [1] . Although some patients have high cure rates, approximately 45% of the patients present with widely disseminated, high-risk disease that remains difficult to cure [2] . NB originates from neural crest precursor cells as a result of genetic and epigenetic alterations that disrupt the normal developmental program. It has been reported that a CpG island methylator phenotype (CIMP) is a powerful prognostic factor, independent of age and stage in NB [3] . In preclinical studies, NB tumor growth is impaired using agents that inhibit DNA methyltransferase agents, indicating the important role that the epigenome plays in NB tumor growth [4, 5] .
Histone acetylation and DNA methylation are epigenetic modifications whose patterns can be considered as heritable marks that ensure accurate transmission of the chromatin states and gene expression profiles over many cell generations [6, 7] . Importantly, patterns and levels of DNA methylation and histone acetylation are markedly changed in human cancers. It has been shown that an epigenetic interplay between DNA methylation and histone acetylation may be involved in the alteration in gene transcription and aberrant gene silencing in a variety of cancers. We have shown previously that 5-aza-2 0deoxycytidine (5-aza-dC), an inhibitor of DNA methyltransferases (DNMTs), is able to increase thrombospondin-1 (THBS1) expression by inducing alteration in histone codes in the promoter region, leading to an accessible chromatin structure [8] .
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is a short-chained fatty acid with a broad spectrum of antiepileptic activities. It is also used in migraine prophylaxis, the treatment of bipolar disorders, and neuropathic pain [9, 10] . In addition, VPA has a wide range of therapeutic applications in many cancer types including breast cancer, glioma, acute myelogenous leukemia, thyroid cancer, endometrial carcinoma, and NB [11] [12] [13] . However, little is known about the molecular mechanism underlying its antitumor activity. In this study, we examined the effects of VPA on NB cell proliferation, expression levels of nine cancer-related genes, promoter methylation of tumor suppressor genes THBS1 and RASSF1A, and overall DNA methylation.
Materials and methods

Neuroblastoma cell culture
Two MYCN-amplified NB cell lines, LA1-55n and NBL-W-N, were used as described previously [8, 14] .
LA1-55n and NBL-W-N cells were grown at 5% CO 2 in RPMI 1640 (Invitrogen, Carlsbad, California, USA) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen), L-glutamine, and antibiotics.
Valproic acid and trichostatin A treatment
VPA and trichostatin A (TSA) were purchased from Sigma (St Louis, Missouri, USA). Cells were treated with the HDAC inhibitor VPA at concentrations of 0.25, 0.5, 1.0, 2.5, and 5.0 mmol/l for 1, 2, and 3 days for cell proliferation assays. The cells were also treated with TSA for 1 day at concentrations of 0.005, 0.05, 0.1, and 0.25 mmol/l for cell proliferation. For flow cytometry and gene expression experiments, cells were treated with 2.5 and 1 mmol/l VPA for 2 and 7 days, respectively. Cells were treated for 2 days with 2.5 mmol/l and 7 days with 1.0 mmol/l VPA, and treated with TSA at a concentration of 1 mg/ml for 7 days for methylation-sensitive highresolution melting (MS-HRM) analysis, and liquid chromatography-mass spectroscopy was performed in NB cells treated with 1 mmol/l VPA and 1 mg/ml TSA for 7 days.
Cell proliferation assay
Cell proliferation was performed using an MTS colorimetric assay and a BrdU incorporation assay. For MTS colorimetric assays, LA1-55n and NBL-W-N cells were seeded into 96-well plates at a density of 5 Â 10 3 cells/ well. After 24 h, VPA was added at various concentrations to each quadruplicate well. Following 1, 2, or 3 days of treatment, MTS labeling mixture (Promega, Madison, Wisconsin, USA) was added, and cells were further incubated for 3 h. The absorbance of the samples was measured using a Synergy 2 Microplate Reader (BioTek Instruments, Winooski, Vermont, USA). For BrdU incorporation assays, BrdU label solution (Millipore, Billerica, Massachusetts, USA) was added to each well 15-18 h before analysis. Denaturing solution was added for 30 min at room temperature after removing the contents of wells. Then, anti-BrdU antibody was added to each well and incubated for 1 h and peroxidase goat anti-mouse IgG HRP conjugate was added to the well for 30 min at room temperature. The absorbance was read at 450-540 nm on a Glomax Multiple Detection System (Promega).
Flow cytometry for analysis of cell cycle NBL-W-N and LA1-55n cells were harvested at the completion of the respective VPA treatments and washed with PBS (pH 7.4) twice and then fixed with 70% ethyl alcohol for 15 min on ice. Subsequently, the cells were centrifuged at 2000 rpm to obtain pellets and residual alcohol was aspirated. Cells were then treated with DNasefree RNase A (2 mg/ml) for 30 min at 371C. Before flow cytometric analysis, cells were resuspended in 1 ml of 10 mg/ml propidium iodide (PI) (Sigma) for staining cellular DNA, as described previously [15] . Cellular DNA content was then analyzed using an Epics XL-MCL Flow Cytometer (Beckman Coulter, Fullerton, California, USA).
Caspase assays
Caspase 3/7 activities in LA1-55n and NBL-W-N cells were measured using the Caspase-Glo assay kit (Promega). The luminescence of each sample was measured in a luminometer according to the manufacturer's instructions (Promega).
cDNA synthesis and SYBR green real-time polymerase chain reaction RNA was isolated from untreated and VPA-treated LA1-55n and NBL-W-N cells using Trizol reagent (Invitrogen). Reverse transcription was performed using SuperScript III (Invitrogen) and 50 mmol/l oligo(dT)20 at 501C for 50 min. SYBR green real-time PCR reactions were set up containing 1 Â Power SYBR Green Master Mix (Applied Biosystems, Foster City, California, USA), and 250 nmol/l forward and reverse primers in a 20 ml reaction. All assays were carried out in a 96-well format. Real-time fluorescence detection of PCR products was performed using a 7500 Fast Real-Time PCR System (Applied Biosystems) under the following thermocycling conditions: 1 cycle of 501C for 2 min and 951C for 20 s; 40 cycles of 951C for 30 s; and 601C for 1 min. The primers used and the reaction conditions were the same as those described previously [8] . For data analysis, the comparative method (DDC t ) was used to calculate the relative quantities of a nucleic acid sequence. Nontreated LA1-55n and NBL-W-N cells were used as the calibrator sample, and GAPDH was used as an endogenous control.
Western blot analysis
Total protein from NBL-W-N and LA1-55n NB cells was extracted after lysing the cells in RIPA buffer (20 mmol/l Tris-HCl pH 7.5, 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l EGTA, 1% IGEPAL, 2.5 mmol/l sodium pyrophosphate, and 1 mmol/l b-glycerophosphate) containing protease and phosphatase inhibitor cocktails (Sigma), and protein concentrations were determined using a Bradford protein assay kit (Bio-Rad, Hercules, California, USA). Equal amounts of total protein (25 mg) from cells were subjected to SDS-polyacrylamide gel electrophoresis and proteins were transferred to a nitrocellulose membrane for 90 min at 100 V. Membranes were blocked for 1 h at room temperature in Tris-buffered saline (TBS) containing 5% nonfat powdered milk and probed with the primary antibody (anti-AcH4; Abcam, Cambridge, Massachusetts, USA) in TBS with 2.5% nonfat powdered milk at a 1 : 1000 dilution and preincubated overnight. A secondary antibody labeled with horseradish peroxidase (GE Healthcare, Piscataway, New Jersey, USA) was used at a 1 : 10 000 dilution for 1 h at room temperature, and immunoreactive bands were detected using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, Illinois, USA) and recorded on a photosensitive film. Tubulin (Sigma) was used as a loading control. 
DNA isolation and bisulfite modification
Total genomic DNA was extracted from the NB cell lines using the Puregene Core Kit A (Qiagen, Valencia, California, USA) and modified by sodium bisulfite using the EZ DNA Methylation-Direct kit (Zymo Research, Irvine, California, USA) according to the manufacturer's protocol.
DNA methylation analysis
MS-HRM technology [16] was used to determine the degree of methylation along the promoter regions of THBS1 and RASSF1A. PCR amplification and HRM analysis were performed on a 7500 Fast Real-Time PCR System. The 97 bp amplicon of THBS1 with 10 CpG dinucleotides was amplified with the sense primer 5 0 -GG TCGGAGGAATTTTTAGGAATG-3 0 and the antisense primer 5 0 -CCTAAACTCGCAAACCAACT-3 0 . MS-HRM for RASSF1A was performed as described previously [17] . PCR reactions were performed in triplicate in a 20 ml volume containing 1 Â buffer, 2 U Hotstart Taq DNA polymerase (Qiagen), 250 nmol/l of each primer, 1.5 mmol/l SYTO-9, and 10 ng bisulfite-treated DNA template, with 2 mmol/l final MgCl 2 . The cycling conditions were as follows: 1 cycle at 951C for 10 min, 40 cycles at 951C for 15 s, and 601C for 1 min, followed by an HRM step of 951C for 10 s, 601C for 1 min, and continuous acquisition to 951C at 1 acquisition per 0.31C, and 601C for 15 s. A standard curve with known methylation ratios was included in each assay and was used to determine the methylation ratio of treated and untreated cells. Universal methylated and unmethylated DNAs were purchased from Millipore. HRM data were analyzed using the High-Resolution Melting Software (Applied Biosystems).
Liquid chromatography-mass spectroscopy
Analysis of total cytosine methylation was performed by liquid chromatography-mass spectroscopy (LC/MS) as described previously [18] . Briefly, genomic DNA from LA1-55n and NBL-W-N was hydrolyzed to nucleosides by adding 5 U nuclease P1 (Sigma) at 371C for 2 h, 0.002 U of venom phosphodiesterase I (Sigma) at 371C for 2 h, and 0.5 U of alkaline phosphatase at 371C for 1 h. Stock solutions of 2 0 -deoxycytidine and 5-methyl-2 0 -deoxycytidine were prepared in water. An eight-point stock mixture of a standard was carefully prepared to yield an exact known concentration ratio of 2 0 -deoxycytidine to 5-methyl-2 0 -deoxycytidine. The concentration of 2 0 -deoxycytidine and 5-methyl-2 0 -deoxycytidine in each sample was calculated from the standard curve. Each DNA sample was analyzed in triplicate. Twenty-five microliters (80 ng) of sample was injected into the LC and run through an Atlantis DC18 silica column (Waters Corporation, Milford, Massachusetts, USA), and 2 0 -deoxycytidine and 5-methyl-2 0 -deoxycytidine was identified by mass spectra of chromatographic peaks.
Statistical analyses
Statistical analyses were performed using a two-tailed Student's t-test. A P value of less than 0.05 was considered statistically significant.
Results
Inhibition of histone deacetylase significantly decreased neuroblastoma cell proliferation in vitro MTS colorimetric assays were performed to determine the effect of VPA on NB cell growth. As shown in Fig. 1a , VPA inhibited the cell proliferation of NBL-W-N in a dose-dependent and time-dependent manner. After 1 day of treatment with VPA, cell proliferation was decreased at concentrations of 2.5 mmol/l and 5 mmol/l (P < 0.01). There was no inhibitory effect of cell growth at a concentration of 1 mmol/l or below. Cell growth was further inhibited with 2 days of treatment at concentrations of 2.5 and 5 mmol/l. After 3 days of treatment with VPA, cell growth was further inhibited at a concentration of 1 mmol/l (P < 0.01). A similar inhibitory effect by VPA was also found in LA1-55n NB cells as shown in Fig. 1b . After 3 days of treatment with VPA, cell proliferation of LA1-55n cells was decreased by B90% compared with an B75% decrease in NBL-W-N cells.
To further determine the effect of VPA on cell proliferation, the BrdU incorporation assay was performed in LA1-55n NB cells in addition to the metabolic activity assays above. As shown in Fig. 1c , VPA decreased DNA synthesis markedly in a dose-dependent manner in LA1-55n cells. TSA is a well-known potent inhibitor of HDAC.
To determine whether TSA has a similar inhibitory effect of cell proliferation in NB, LA1-55n cells were treated with varied concentrations of TSA and subjected to a BrdU incorporation assay. As shown in Fig. 1d , TSA exerted an antiproliferation effect in a dose-dependent manner.
Inhibition of histone deacetylase blocked cell cycle progression
Flow cytometry analysis was performed to determine whether VPA induced cell cycle arrest. As shown in Fig. 2a and b, cell cycle arrest at G 1 was observed following the treatment of NBL-W-N and LA1-55n cells with VPA at a concentration of 2.5 mmol/l for 2 days (P < 0.01).
It has been reported that concentrations of VPA above 2 mmol/l are cytotoxic to NB cell lines [13] . To determine whether inhibition of HDAC attenuated cell proliferation through the apoptotic pathway, caspase 3/7 activity was measured. As shown in Fig. 2c and d, no significant difference in caspase 3/7 activity was observed between VPA-treated and vehicle-treated NB cells after treatment with VPA for 1 day. However, a significant increase in caspase 3/7 activity was observed in both NBL-W-N and LA1-55n cells after treatment with VPA at 2.5 mmol/l for 2 and 3 days, respectively.
Inhibition of histone deacetylase modulated the expression pattern of cancer-related genes
Expression studies indicated changes in the levels of nine cancer-related genes following treatment with VPA. As shown in Fig. 3a , the level of expression of seven genes (THBS1, CASP8, SPARC, CDKN1A, HIC1, CDKN1B, and HIN1) was significantly upregulated in the VPA-treated NBL-W-N cells. HIN1 was especially sensitive in NBL-W-N cells and the level of transcript expression was increased by seven-fold following 2 days of treatment. In contrast, TIG1 and MYCN were downregulated in NBL-W-N cells treated with VPA ( Fig. 3a , P < 0.01).
A similar expression pattern was observed in LA1-55n cells treated with 2.5 mmol/l VPA for 2 days. The seven genes whose expression was upregulated in NBL-W-N cells treated with VPA were found to have increased gene expression in LA1-55n cells as well (Fig. 3b ). The expression of CASP8 was increased over 20-fold. In addition, similar downregulation of MYCN and TIG1 was observed in LA1-55n cells. We also examined the expression of these nine genes in both cell lines treated with VPA for 1 and 3 days, respectively. A similar expression pattern was observed in both cell lines as with 2 days of treatment (data not shown). 
Inhibition of histone deacetylase increased acetylation of histone H4
To determine whether the VPA-induced inhibitory effect of cell proliferation in NB was through histone modification, the acetylation level of histone H4 was examined by western blot analysis using an antibody against acetyl histone H4. As shown in Fig. 4a , the level of acetylation of histone 4 was markedly increased in NBL-W-N cells after treatment with VPA at concentrations of 1 and 2.5 mmol/l for 1 day. As a positive control, TSA at a concentration of 1 mg/ml upregulated the acetylation level of histone H4. Similar results were found in LA1-55n NB cells after treatment with VPA and TSA, respectively, as shown in Fig. 4b .
Time-course gene-specific methylation modulated by inhibition of histone deacetylase
To determine whether inhibition of HDAC mediates gene-specific methylation changes, MS-HRM analysis was performed, and the levels of THBS1 and RASSF1A
promoter methylation were analyzed in LA1-55n cells treated with VPA for 2 and 7 days, respectively. THBS1 was selected, as we have previously shown that its expression is regulated by both DNA methylation and histone modification of the promoter region [5, 8] . We also selected RASSF1A as a target, as we have shown previously that methylation of RASSF1A was associated with poor outcome in NB [19] . As shown in Fig. 5a , the sensitivity of the THBS1 HRM analysis was examined by using dilutions of fully methylated DNA with unmethylated DNA and subsequent amplification with THBS1 primers. The HRM standard melting curve was derived from seven samples with the content of methylated DNA (0, 1, 10, 25, 50 75, and 100%). At the annealing temperature of 601C, such methylation levels can be easily distinguished, and as low as 1% of methylation can be detected. As shown in Fig. 5b , we observed a distinct shift in the melting profile, which indicates that VPA treatment for 7 days resulted in a reduced methylation level of the THBS1 promoter in LA1-55n NB cells. The sensitivity of the RASSF1A HRM analysis was also examined using RASSF1A primers. As shown in Fig. 6a , the methylation levels of RASSF1A can also be easily distinguished and 1% of methylation could be detected. VPA treatment for 7 days resulted in a reduced methylation level of the RASSF1A promoter in LA1-55n NB cells as evidenced by the left shift in the melting curve ( Fig. 6b ).
To determine whether VPA altered the DNA methylation level around THBS1 and RASSF1A promoter regions within a relatively short period time of treatment, HRM analysis was performed in LA1-55n cells after treatment with VPA for 2 days. There was no difference in the methylation level around THBS1 and RASSF1A promoter regions (data not shown).
To determine whether other HDAC inhibitors exert a similar effect of altered THBS1 and RASSF1A promoter methylation, TSA, a potent HDAC inhibitor, was used. As shown in Fig. 7a and b, TSA treatment resulted in decreased methylation levels of RASSF1A and THBS1 promoters as evidenced by the left shift in the melting curve.
Long-term effect of valproic acid treatment on gene expression
To determine whether relatively short (2 days) and long (7 days) treatments of VPA exerted distinct effects on gene expression, we measured the gene expression levels of THBS1 and CASP8 in LA1-55n cells treated with 1 mmol/l VPA for 7 days. As shown in Fig. 8a , the expression of THBS1 was further increased compared with the expression in LA1-55n cells treated with VPA for 2 days (Fig. 3) . The expression of CASP8 in LA1-55n cells treated with VPA for 7 days was also higher compared with the control. However, the increase in CASP8 expression following 7 days of treatment was not as high as with 2 days of treatment (Fig. 8b) . 
Inhibition of histone deacetylase altered overall DNA methylation
To examine whether inhibition of HDAC affects genomewide epigenetic changes, we compared the overall DNA methylation levels in the NBL-W-N and LA1-55n cells with and without VPA treatment. Using a standard curve average of 5-methylcytosine ( Fig. 9a ), the level of 5-methylcytosine was increased significantly (P < 0.01) by 1.4-and two-fold in VPA-treated NBL-W-N and LA1-55n cells compared with the controls (Fig. 9b and c) , indicating that inhibition of HDAC by VPA induces modulation of the epigenome. To determine whether TSA alters the overall DNA methylation level, NBL-W-N and LA1-55n NB cells were treated with TSA for 7 days and LC-MS was performed. As shown in Fig. 9d and e, there is no significant difference in the level of total 5-methylcytosine in TSA-treated cells compared with the controls.
Discussion
Epigenetic changes play an important role in the pathogenesis of cancer, and a CIMP has been shown to be predictive of poor outcome [3, 20, 21] . The effect of HDAC inhibition on NB cells has been investigated intensively by several groups [12, [22] [23] [24] . In this study, we examined the role of HDAC in cell proliferation, cell cycle progression, gene expression, gene-specific methylation, and global methylation status in two MYCNamplified tumorigenic NB cell lines (LA1-55n and NBL-W-N). We show that inhibition of HDAC by VPA significantly decreased NB cell proliferation in vitro in a dose-dependent and time-dependent manner, and induced G 1 growth arrest in LA1-55n and NBL-W-N NB cell lines. Consistent with the mechanism of VPA action, these changes were associated with an increase in overall methylation and a corresponding decrease in the expression level of the MYCN oncogene. In contrast, the expression levels of genes that suppress tumor progression were increased. Gene-specific analysis showed that despite the increase in overall methylation, promoters of tumor suppressor genes THBS1 and RASSF1A were hypomethylated after VPA treatment, indicating a redistribution of the methylation pattern that is mediated by VPA. Epigenetics plays an established role in promoting pathological cell proliferation in cancers because of the decreased expression of tumor suppressor genes. Our present study indicates that VPA is able to rescue the expression of tumor suppressor genes, and tumorigenic expression profiles in NB can be modulated to a benign expression pattern by inhibition of HDAC. For instance, the expression of both CDKN1A and CDKN1B was upregulated in VPA-treated NB cells. CDKN1A and CDKN1B genes encode potent cyclin-dependent kinase inhibitors, which are silenced in several malignancies [25, 26] . The encoded proteins for CDKN1A and CDKN1B have been reported to function as regulators of cell cycle progression at G 1 [27] . The mechanism of both CDKN1A and CDKN1B regulation and its consequences parallel those discovered recently in human cancers [27, 28] . An inverse correlation was found between the expression of CDKN1A and CDKN1B and cell proliferation in NB cells treated with VPA in our study. In our previous preclinical model, tumor cell proliferation was inhibited by VPA, indicating that VPA may target NB tumor cells [12] . Our present study showed that modulation of the epigenome is a critical link between the expression of cell cycle-related genes and the regulation of cell proliferation.
In the pediatric cancer NB, clinically aggressive disease is associated with increased levels of angiogenesis stimulators and a high vascular index. THBS1 and SPARC encode proteins that function as antiangiogenesis factors in NB. THBS1 is a well-known natural inhibitor of angiogenesis. The regulation of THBS1 plays an important role in the angiogenic switch in many tumor types [29, 30] and we have shown that ABT510, a THBS1 peptide, inhibited the growth of NB in preclinical models [12] . Further, THBS1 expression is upregulated, angiogenesis is inhibited, and NB tumor growth is impaired following treatment with the demethylating agent, 5-aza-dC [5] . Here, we show that VPA also modifies the pattern of DNA methylation in the THBS1 promoter and induces expression of the gene. Previously, we have shown that SPARC is a key antiangiogenesis factor in NB [31] , and modulation of SPARC expression is mediated by the differentiation agent retinoic acid as well as 5-aza-dC, an inhibitor of DNMT [8, 31] . In this study, VPA induced THBS1 and SPARC expression in NB cells, indicating that histone modification is involved in the regulation of THBS1 and SPARC. The present study supports a key role for THBS1 and SPARC as the link between the angiogenic and epigenetic switches.
CASP8 encodes a member of the cysteine-aspartic acid protease (caspase) family. The sequential activation of caspases plays a central role in the execution phase of cell apoptosis. The methylation of CASP8 was initially identified in NB patients with amplification of MYCN [32] . Because of the marked upregulation of CASP8 expression that was observed in the LA1-55n cells following treatment with VPA, it is quite possible that VPA induces decreased cell growth not only because of cell cycle arrest but also because of cell apoptosis. Our data indicated that although a significant difference was not found in caspase 3 activity between vehicle-treated and VPA-treated cells, the trend toward an increase in caspase activity was observed in VPA-treated NB cells for 1 day treatment. A significant increase of caspase activity was observed in NB cells treated with VPA for 2 and 3 days. It was reported recently that VPA induced apoptosis and affected the acetylation status of p53 in prostate cancer cells [30] . TSA, another potent inhibitor of HDAC, exerted antiproliferation effects through induction of cell apoptosis in several cancer cell types [33, 34] .
HIC1 is a molecule that controls cell growth [35] . We have shown previously that the expression of HIC1 is upregulated in NB cells treated with 5-aza-dC. In this study, the expression of HIC1 was increased following treatment with VPA, indicating that histone modification/ acetylation level is involved in the regulation of HIC1 expression. HIN1 is a putative cytokine with growthinhibitory activities [36] . HIN1 was initially found to be significantly downregulated in human breast carcinomas and in preinvasive lesions. Although the evidence linking HIN1 levels to the NB phenotype is unknown, our previous study indicated that the methylation of HIN1 is associated with poor outcome in NB [14] . In this study, we found that the expression of HIN1 was upregulated by VPA and is associated with the modulation of the NB phenotype.
MYCN and TIG1 are the two genes whose expression was downregulated by VPA. MYCN is considered to be a potential specific target for therapy of NB. Our study showed that VPA resulted in a decrease in the expression of MYCN that correlated with inhibited cell proliferation and cell cycle arrest. The effect of downregulation of MYCN by VPA in NBL-W-N and LA1-55n NB cells is consistent with previous observations [12, 13] , indicating that a decrease in MYCN expression by VPA in NB cell lines is a common phenomenon. Our data are also in good agreement with previous studies showing that reduction in MYCN mRNA with the use of antisense MYCN can inhibit proliferation and/or induce differentiation in NB cell lines [37, 38] . Although there are studies showing MYCN-mediated signal pathways, leading to alteration in the NB phenotype, the molecular mechanism underlying the regulation of MYCN in NB is largely unknown. There are some other studies showing that the expression of MYCN can be regulated by differentiation agents. Treatment of MYCN-amplified NB cells with retinoic acid has been shown to cause NB cells to undergo G 1 arrest and differentiation along with downregulation of MYCN [39] . Importantly, overexpression of MYCN counteracts retinoic acid-induced G 1 arrest and differentiation [40] . TIG1 expression was also downregulated by VPA in this study, and not paralleled with a change in TIG1 by 5-aza-dC, an inhibitor of DNMTs, as we have described previously [8] . It is possible that besides a cell-specific effect, the expression of TIG1 is regulated because of its promoter hypermethylation.
Cancer cells are characterized by a generalized disruption of the DNA methylation pattern involving an overall decrease in the level of 5-methylcytosine along with regional hypermethylation of particular CpG islands. During the development of neoplasms, the degree of hypomethylation of genomic DNA increases as the lesion progresses from a benign proliferation of cells to an invasive cancer [41, 42] . The decrease in DNA methylation is mainly because of the hypomethylation of repetitive DNA sequences and demethylation of some coding regions and introns. The distribution of DNA is altered in a variety of normal cellular processes, including generation of chromosomal instability, reactivation of transposable elements, and loss of imprinting, leading to an increased risk of cancer [43] . As VPA is an HDAC inhibitor, one may expect that VPA initially targets histone modification and later modulates the DNA methylation. We found that the acetylation level of histone 4 was modulated by VPA. After 1 day of treatment with VPA, we observed an increased level of acetylation of histone 4. However, a VPA-induced decrease in promoter hypermethylation of THBS1 and RASSF1A was not observed within 2 days of treatment with VPA, but an alteration in promoter hypermethylation of THBS1 and RASSF1A was observed after 7 days of VPA treatment, indicating that reprogramming of methylation in certain promoter regions is time-course dependent on VPA treatment. Interestingly, although TSA treatment resulted in a reduction in the methylation status of RASSF1A and THBS1, there was no significant change in overall 5-methylcytosine in TSA-treated and untreated NB cells, indicating that the effects of VPA and TSA on the DNA methylation patterns may differ. More importantly, an inverse relationship between THBS1 expression and the extent of DNA methylation was observed in the LA1-55n cells treated with VPA for 2 and 7 days, respectively.
A VPA-induced demethylation study has been reported previously [44] , which showed that RELN and GAD (67) promoter demethylation was considerably accelerated after the administration of VPA to mice for 48-72 h. VPA effectively increased the binding of acetyl histone-3 to RELN and GAD (67) promoters, suggesting that histone-3 covalent modifications modulate DNA demethylation. Our study supports the view that HDAC inhibitors facilitate DNA demethylation. In addition, quantitative analysis of overall 5-methylcytosine levels by LC/MS indicated that inhibition of HDAC resulted in the rescue of overall DNA methylation levels in both NB cell lines. According to our gene-specific and global methylation analysis, inhibition of HDAC is capable of altering the distribution of DNA methylation, which is associated with changes in the NB phenotype. Our studies indicated that VPA, as an HDAC inhibitor, is not only able to modulate histone modification but also alter genome-wide DNA methylation. To our knowledge, this is the first report to show that VPA modulates overall DNA methylation. That is also consistent with our previous studies showing that an interplay between histone methylation and DNA methylation occurred in NB [8] . The extent of both DNA hypomethylation and hypermethylation in NB cells is likely to indicate distinctive biological and clinical characteristics.
Taken together, our results indicate that the inhibition of HDAC is capable of modulating the NB phenotype by altering the expression pattern and the epigenome of NB.
Understanding the role of the interaction between histone modification and DNA methylation, and how they function at the molecular level may shed light on the mechanisms involved in the development and progression of NB.
Conclusion
Our data indicated that inhibition of HDAC blocked NB cell proliferation and induced cell cycle arrest. We also showed that inhibition of HDAC decreased the level of promoter methylation in two tumor suppressor genes (THBS1 and RASSFIA), increased global DNA methylation, and modified the level of expression of cancerrelated genes toward a nontumorigenic pattern. These studies indicate that the histone modifier, VPA, may exert antitumor effects through alteration of DNA methylation status and patterns. Further studies examining the antitumor effects of VPA in high-risk NB are warranted.
